Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis.
Despite numerous studies aimed at verifying the anti-tumour activity of aspirin on colon carcinogenesis little is known on the molecular targets involved in the anti-carcinogenic properties of this drug. We investigated the long-term administration of low dose of aspirin in a model of experimental colon carcinogenesis in rats. Adult Wistar rats received an intraperitoneal injection of azoxymethane (AOM) once a week for two weeks in order to initiate colon carcinogenesis. One week after AOM injection, rats received daily 0.01% aspirin (6 mg/kg body weight) in drinking water for 10 months. Compared to AOM control rats, aspirin treatment for 10 months caused a 50% reduction of the number of aberrant crypt foci associated with a 50% reduction of prostaglandin E2 (PGE2) concentration and suppressed by 80% tumour formation in the colon. RT-PCR quantitative analysis showed that aspirin treatment reduced significantly (P<0.01) the AOM-triggered increase in mRNA levels of soluble inflammatory mediators (TNFalpha and IL-1beta) and metalloproteinases (MMP3 and MMP7). Conversely, we detected an increased expression level of alpha-defensin-5 (Rd-5, 2 fold) and lipocalin-2 (LCN2, 4 fold), two markers of the innate immunity system. The expression of apoptosis-related genes such as death receptors and their ligands were reduced by aspirin and the Bcl-2/Bax transcript ratio droped, Bcl-2 expression being reduced to the level found in saline control rats. The present study identifies new molecular targets triggered by aspirin in the colonic mucosa and may support the use of non-toxic low dose of aspirin in long-term treatments as a prophylactic approach against colon carcinogenesis.
Bousserouel
Souad
S
University of Strasbourg Unit EA 4438, Faculty of Medicine, Laboratory of Nutritional Cancer Prevention, Strasbourg, France.
Gosse
Francine
F
Bouhadjar
Mourad
M
Soler
Luc
L
Marescaux
Jacques
J
Raul
Francis
F
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology*; D001397:Azoxymethane; D002273:Carcinogens; D002277:Carcinoma / Q000139:chemically induced / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects* / Q000235:genetics; D003110:Colonic Neoplasms / Q000139:chemically induced / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D004353:Drug Evaluation, Preclinical; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D007113:Immunity, Innate / Q000187:drug effects / Q000235:genetics; D018836:Inflammation Mediators / Q000378:metabolism; D008297:Male; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000235:genetics / Q000276:immunology / Q000517:prevention & control; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D002273:Carcinogens; D018836:Inflammation Mediators; D001397:Azoxymethane; D001241:Aspirin